Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination

Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination

US Patent 9650614 · Granted May 16, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRI2022
High throughput genome-wide translocation sequencing2019
High throughput genome-wide translocation sequencing2016
Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination2015
Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination2015
Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination2015
p185neu-encoding DNA and therapeutical uses thereof2013
p185neu-encoding DNA and therapeutical uses thereof2012
Plasmids coding for p185neu protein sequence variants and therapeutic uses there2012
Regulation of expression of PI3Kβ protein in tumors2012
Plasmids coding for p185neu protein sequence variants and therapeutic uses there2011
Human Rgr oncogene and truncated transcripts thereof detected in T cell malignan2011